To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Nevins AK, Thurmond DC
Para evitar los efectos secundarios, aumenta la dosis poco a poco Los efectos secundarios de la semaglutida tienden a ser leves, dice Kirby, aunque muchos usuarios nuevos experimentan problemas gastrointestinales, como nuseas
For FDA-approved treatments, qualified individuals may be prescribed Ozempic, Wegovy, and Mounjaro
It simplifies the entire process of planning and preparing correct peptide doses for research or lab use